1
|
Breuer J, Garzinsky AM, Thomas A, Kliesch S, Nieschlag E, Wenzel F, Georgas E, Geyer H, Thevis M. Investigations into the Concentrations and Metabolite Profiles of Doping Agents and Antidepressants in Human Seminal Fluid Using Liquid Chromatography-Mass Spectrometry. Drug Metab Dispos 2024; 52:1313-1322. [PMID: 39168526 DOI: 10.1124/dmd.124.001845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 08/15/2024] [Accepted: 08/19/2024] [Indexed: 08/23/2024] Open
Abstract
Exogenous substances, including drugs and chemicals, can transfer into human seminal fluid and influence male fertility and reproduction. In addition, substances relevant in the context of sports drug testing programs, can be transferred into the urine of a female athlete (after unprotected sexual intercourse) and trigger a so-called adverse analytical finding. Here, the question arises as to whether it is possible to distinguish analytically between intentional doping offenses and unintentional contamination of urine by seminal fluid. To this end, 480 seminal fluids from nonathletes were analyzed to identify concentration ranges and metabolite profiles of therapeutic drugs that are also classified as doping agents. Therefore, a screening procedure was developed using liquid chromatography connected to a triple quadrupole mass spectrometer, and suspect samples (i.e., samples indicating the presence of relevant compounds) were further subjected to liquid chromatography-high-resolution accurate mass (tandem) mass spectrometry. The screening method yielded 90 findings (including aromatase inhibitors, selective estrogen receptor modulators, diuretics, stimulants, glucocorticoids, beta-blockers, antidepressants, and the nonapproved proliferator-activated receptor delta agonist GW1516) in a total of 81 samples, with 91% of these suspected cases being verified by the confirmation method. In addition to the intact drug, phase-I and -II metabolites were also occasionally observed in the seminal fluid. This study demonstrated that various drugs including those categorized as doping agents partition into seminal fluid. Monitoring substances and metabolites may contribute to a better understanding of the distribution and metabolism of exogenous substances in seminal fluid that may be responsible for the impairment of male fertility. SIGNIFICANCE STATEMENT: This study demonstrates that doping agents as well as clinically relevant substances are transferred/eliminated into seminal fluid to a substantial extent and that knowledge about drug levels (and potential consequences for the male fertility and female exposure) is limited. The herein generated new dataset provides new insights into an important and yet little explored area of drug deposition and elimination, and hereby a basis for the assessment of contamination cases by seminal fluid in sports drug testing.
Collapse
Affiliation(s)
- Johanna Breuer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Ann-Marie Garzinsky
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Andreas Thomas
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Sabine Kliesch
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Eberhard Nieschlag
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Folker Wenzel
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Evangelos Georgas
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Hans Geyer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| | - Mario Thevis
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany (J.B., A-M. G., A.T., H.G., M.T.); University Hospital Muenster (UKM), Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Muenster, Germany (S.K., E.N.); Faculty of Medical and Life Sciences, Furtwangen University, Villingen-Schwenningen, Germany (F.W.); Centre for Urology, Neuss, Germany (E.G.); and European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany (H.G., M.T.)
| |
Collapse
|
2
|
Xie X, Zhang X, Chen T, Yu D, Ma M, Lu X, Xu G. High-coverage identification of hydroxyl compounds based on pyridine derivatization-assisted liquid chromatography mass spectrometry. Anal Chim Acta 2024; 1322:343065. [PMID: 39182991 DOI: 10.1016/j.aca.2024.343065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 07/29/2024] [Accepted: 08/05/2024] [Indexed: 08/27/2024]
Abstract
Hydroxyl compounds are widely present in plants and play essential roles in plant growth and development. High-coverage detection of hydroxyl compounds is crucial for understanding the physiological processes of plants. Despite the prevalence of chemical derivatization-assisted liquid chromatography-high resolution mass spectrometry (CD-LC-HRMS) in high-coverage detection of compounds with diverse functional groups, the confident identification of these compounds after derivatization remains a significant challenge. Herein, a novel method was developed for the identification of pyridine (PY)-derivatized hydroxyl compounds by comparing the MS/MS similarity of derivatized and corresponding underivatized compounds. Fragmentation rules of standards were summarized, and theoretical calculations have demonstrated the MS/MS similarity of PY-derivatized hydroxyl compounds with their underivatized counterparts. The effectiveness of the developed method was demonstrated by identifying PY-derivatized authentic standards. A total of 90 hydroxyl compounds were putatively identified in maize using the proposed method. This method can significantly enhance ionization efficiency with minimal impact on the quality of the MS/MS spectra, enabling the effective utilization of mass spectra databases for the identification of hydroxyl compounds.
Collapse
Affiliation(s)
- Xiaoyu Xie
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; Key Laboratory of Phytochemical R&D of Hunan Province, Hunan Normal University, Changsha, 410081, China
| | - Xiuqiong Zhang
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China
| | - Tiantian Chen
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China
| | - Di Yu
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; Liaoning Province Key Laboratory of Metabolomics, Dalian, 116023, China
| | - Ming Ma
- Key Laboratory of Phytochemical R&D of Hunan Province, Hunan Normal University, Changsha, 410081, China
| | - Xin Lu
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; Liaoning Province Key Laboratory of Metabolomics, Dalian, 116023, China.
| | - Guowang Xu
- CAS Key Laboratory of Separation Science for Anal. Chem, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; Liaoning Province Key Laboratory of Metabolomics, Dalian, 116023, China.
| |
Collapse
|
3
|
Temerdashev A, Zorina M, Feng YQ, Gashimova E, Dotsenko VV, Ioutsi V, Atapattu SN. Cyanoacetohydrazide as a Novel Derivatization Agent for the Determination of UHPLC-HRMS Steroids in Urine. Molecules 2024; 29:2433. [PMID: 38893309 PMCID: PMC11173670 DOI: 10.3390/molecules29112433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Revised: 04/20/2024] [Accepted: 05/20/2024] [Indexed: 06/21/2024] Open
Abstract
The possibility of cyanoacetohydrazide usage as a novel derivatizing agent is demonstrated in the presented article, and a comparison with hydroxylamine as the most commonly used reagent is provided. Optimal conditions for steroid derivatization with cyanoacetohydrazide are provided. According to the collected data, the maximum yield of derivatives was observed at pH 2.8 within 70 min at 40 °C with 5 ng/mL limit of detection for all investigated analytes. It was shown that cyanoacetohydrazide derivatives produces both syn- and anti-forms as well as hydroxylamine, and their ratios were evaluated and shown in presented work. An efficiency enchantment from two to up to five times was achieved with a novel derivatization reagent. Its applicability for qualitative analysis of steroids in urine was presented at real samples. Additionally, the reproducible fragmentation of the derivatizing agent in collision-induced dissociation offers opportunities for simplified non-targeted steroidomic screening. Furthermore, cyanoacetohydrazide increases ionization efficiency in positive mode, which can eliminate the need for redundant high-resolution instrument runs required for both positive and negative mode analyses.
Collapse
Affiliation(s)
- Azamat Temerdashev
- Analytical Chemistry Department, Kuban State University, Krasnodar 350040, Russia
| | - Maria Zorina
- Analytical Chemistry Department, Kuban State University, Krasnodar 350040, Russia
| | - Yu-Qi Feng
- School of Bioengineering and Health, Wuhan Textile University, Wuhan 430415, China
| | - Elina Gashimova
- Analytical Chemistry Department, Kuban State University, Krasnodar 350040, Russia
| | - Victor V. Dotsenko
- Analytical Chemistry Department, Kuban State University, Krasnodar 350040, Russia
| | | | | |
Collapse
|
4
|
Olesti E, Boccard J, Rahban R, Girel S, Moskaleva NE, Zufferey F, Rossier MF, Nef S, Rudaz S, González-Ruiz V. Low-polarity untargeted metabolomic profiling as a tool to gain insight into seminal fluid. Metabolomics 2023; 19:53. [PMID: 37271779 PMCID: PMC10239740 DOI: 10.1007/s11306-023-02020-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 05/15/2023] [Indexed: 06/06/2023]
Abstract
INTRODUCTION A decrease in sperm cell count has been observed along the last several decades, especially in the most developed regions of the world. The use of metabolomics to study the composition of the seminal fluid is a promising approach to gain access to the molecular mechanisms underlying this fact. OBJECTIVES In the present work, we aimed at relating metabolomic profiles of young healthy men to their semen quality parameters obtained from conventional microscopic analysis. METHODS An untargeted metabolomics approach focusing on low- to mid-polarity compounds was used to analyze a subset of seminal fluid samples from a cohort of over 2700 young healthy men. RESULTS Our results show that a broad metabolic profiling comprising several families of compounds (including acyl-carnitines, steroids, and other lipids) can contribute to effectively distinguish samples provided by individuals exhibiting low or high absolute sperm counts. CONCLUSION A number of metabolites involved in sexual development and function, signaling, and energy metabolism were highlighted as being distinctive of samples coming from either group, proving untargeted metabolomics as a promising tool to better understand the pathophysiological processes responsible for male fertility impairment.
Collapse
Affiliation(s)
- Eulalia Olesti
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | - Julien Boccard
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | - Rita Rahban
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
- Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Sergey Girel
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Natalia E Moskaleva
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Fanny Zufferey
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
- Service of Clinical Chemistry & Toxicology, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland
| | - Michel F Rossier
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
- Service of Clinical Chemistry & Toxicology, Central Institute of Hospitals, Hospital of Valais, Sion, Switzerland
- Department of Internal Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Serge Nef
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
- Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland.
| | - Víctor González-Ruiz
- School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
- Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
| |
Collapse
|
5
|
Swart AC, van Rooyen D, du Toit T. Investigating the biosynthesis and metabolism of 11β-hydroxyandrostenedione. Methods Enzymol 2023; 689:387-431. [PMID: 37802580 DOI: 10.1016/bs.mie.2023.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
The "rediscovery" 11β-hydroxyandrostenedione (11OHA4) placed the spotlight on this unique adrenal-derived hormone with researchers and clinicians once again focusing on the steroid's presence in endocrine pathology. Little was known about the steroid other than its chemical characterisation and that a mitochondrial cytochrome P450 enzyme catalysed the 11β-hydroxylation of 11OHA4. The fact that neither the biosynthesis nor metabolism of 11OHA4 had been fully characterised presented an ideal opportunity to investigate the metabolic pathways. In addition, methodologies and analytical tools have improved vastly since 11OHA4 was first identified in the 1950s. Cell models, recombinant DNA technology and steroid quantification using liquid chromatography mass spectrometry have greatly facilitated investigations in the field of steroidogenesis. Evident from the structure is that 11OHA4 can be metabolised by hydroxysteroid dehydrogenases and reductases acting on the C4/C5 double bond and on functional moieties at specific carbons on the cyclopentane-perhydro-phenanthrene backbone of the steroid. In this chapter, the biosynthesis and metabolism of 11OHA4 is followed using two strategies that complement each another; (i) human cell models either transiently transfected with recombinant DNA or expressing endogenous steroidogenic enzymes and (ii) steroid identification and quantification using high resolution mass spectrometry. These methodologies have proven invaluable in the determination of 11OHA4's metabolic route. Both strategies are presented with the focus on the accurate identification and quantification of steroids using UHPLC-MS/MS and UPC2-MS/MS. The protocols described in this chapter lay a sound foundation which can aid the researcher and be adapted and implement in future studies.
Collapse
Affiliation(s)
- Amanda C Swart
- Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa; Department of Chemistry, Stellenbosch University, Stellenbosch, South Africa.
| | - Desmaré van Rooyen
- Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
| | - Therina du Toit
- Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
| |
Collapse
|
6
|
Breuer J, Thomas A, Delahaut P, Schänzer W, Geyer H, Thevis M. Investigations into the concentration and metabolite profiles of stanozolol and LGD-4033 in blood plasma and seminal fluid using liquid chromatography high-resolution mass spectrometry. Anal Bioanal Chem 2023; 415:669-681. [PMID: 36441233 PMCID: PMC9839828 DOI: 10.1007/s00216-022-04456-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 10/27/2022] [Accepted: 11/21/2022] [Indexed: 11/29/2022]
Abstract
Potential scenarios as to the origin of minute amounts of banned substances detected in doping control samples have been a much-discussed problem in anti-doping analysis in recent years. One such debated scenario has been the contamination of female athletes' urine with ejaculate containing doping agents and/or their metabolites. The aim of this work was to obtain complementary information on whether relevant concentration ranges of doping substances are excreted into the ejaculate and which metabolites can be detected in the seminal fluid (sf) and corresponding blood plasma (bp) samples. A method was established to study the concentration and metabolite profiles of stanozolol and LGD-4033-substances listed under anabolic substances (S1) on the World Anti-Doping Agency's Prohibited List-in bp and sf using liquid chromatography high-resolution mass spectrometry (LC-HRMS). For sf and bp, methods for detecting minute amounts of these substances were developed and tested for specificity, recovery, linearity, precision, and reliability. Subsequently, sf and bp samples from an animal administration study, where a boar orally received stanozolol at 0.33 mg/kg and LGD-4033 at 0.11 mg/kg, were measured. The developed assays proved appropriate for the detection of the target substances in both matrices with detection limits between 10 and 40 pg/mL for the unmetabolized drugs in sf and bp, allowing to estimate the concentration of stanozolol in bp (0.02-0.40 ng/mL) and in sf (0.01-0.25 ng/mL) as well as of LGD-4033 in bp (0.21-2.00 ng/mL) and in sf (0.03-0.68 ng/mL) post-administration. In addition, metabolites resulting from different metabolic pathways were identified in sf and bp, with sf resembling a composite of the metabolic profile of bp and urine.
Collapse
Affiliation(s)
- Johanna Breuer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Andreas Thomas
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | | | - Wilhelm Schänzer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Hans Geyer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Mario Thevis
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| |
Collapse
|
7
|
Buszewska-Forajta M, Raczak-Gutknecht J, Struck-Lewicka W, Nizioł M, Artymowicz M, Markuszewski M, Kordalewska M, Matuszewski M, Markuszewski MJ. Untargeted Metabolomics Study of Three Matrices: Seminal Fluid, Urine, and Serum to Search the Potential Indicators of Prostate Cancer. Front Mol Biosci 2022; 9:849966. [PMID: 35309505 PMCID: PMC8931686 DOI: 10.3389/fmolb.2022.849966] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 02/11/2022] [Indexed: 01/16/2023] Open
Abstract
The simultaneous determination of metabolites from biological fluids may provide more accurate information about the current body condition. So far, the metabolomics approach has been successfully applied to study the mechanism of several disorders and to search for novel biomarkers. Urine and plasma are widely accepted matrices for the evaluation of several pathologies, while prostate cancer (CaP) development is still unknown. For this reason, an alternative matrix, the seminal fluid, was proposed to expand the knowledge about the CaP pathomechanism. The main aim of this study was to develop and optimize the sample preparation protocol to ensure the highest coverage of the metabolome of ejaculate samples. Parameters like the type and composition of the solvent mixture, time of extraction, and applied volume of the solvent were tested. The optimized method was applied for the untargeted metabolomics profiling of seminal fluid samples obtained from CaP patients. Moreover, urine and serum samples were also prepared for untargeted metabolomics analysis. Analyses were carried out with the use of two complementary analytical techniques: GC-EI-QqQ/MS and LC-ESI-TOF/MS. Finally, the metabolic signature of seminal fluid (n = 7), urine (n = 7), and plasma (n = 7) samples was compared. Furthermore, the hypothesis of the increased level of metabolites in ejaculate samples related to the CaP development was evaluated. The results indicated that the developed and optimized sample preparation protocol for seminal fluid may be successfully applied for metabolomics study. Untargeted analysis of ejaculate enabled to determine the following classes of compounds: fatty acids, sphingolipids, phospholipids, sugars, and their derivatives, as well as amino acids. Finally, a comparison of the three tested matrices was carried out. To our best knowledge, it is the first time when the metabolic profile of the three matrices, namely, urine, plasma, and seminal fluid, was compared. Based on the results, it can be pointed out that ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples). Compared to plasma, semen samples revealed to have a similar profile; however, determined levels of metabolites were lower in case of ejaculate. In case of urine samples, compared to semen metabolic profiles, the levels of detected metabolites were decreased in the latter ones.
Collapse
Affiliation(s)
- Magdalena Buszewska-Forajta
- Institute of Veterinary Medicine, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Toruń, Torun, Poland
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
- *Correspondence: Magdalena Buszewska-Forajta,
| | - Joanna Raczak-Gutknecht
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
| | - Wiktoria Struck-Lewicka
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
| | - Magdalena Nizioł
- Department of Pharmaceutical and Biopharmaceutical Analysis, Faculty of Pharmacy, Medical University of Białystok, Białystok, Poland
| | - Małgorzata Artymowicz
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
| | - Marcin Markuszewski
- Department of Urology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Marta Kordalewska
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
| | - Marcin Matuszewski
- Department of Urology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Michał J. Markuszewski
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
8
|
|
9
|
|
10
|
Lassi M, Tomar A, Comas-Armangué G, Vogtmann R, Dijkstra DJ, Corujo D, Gerlini R, Darr J, Scheid F, Rozman J, Aguilar-Pimentel A, Koren O, Buschbeck M, Fuchs H, Marschall S, Gailus-Durner V, Hrabe de Angelis M, Plösch T, Gellhaus A, Teperino R. Disruption of paternal circadian rhythm affects metabolic health in male offspring via nongerm cell factors. SCIENCE ADVANCES 2021; 7:7/22/eabg6424. [PMID: 34039610 PMCID: PMC8153725 DOI: 10.1126/sciadv.abg6424] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Accepted: 04/02/2021] [Indexed: 06/12/2023]
Abstract
Circadian rhythm synchronizes each body function with the environment and regulates physiology. Disruption of normal circadian rhythm alters organismal physiology and increases disease risk. Recent epidemiological data and studies in model organisms have shown that maternal circadian disruption is important for offspring health and adult phenotypes. Less is known about the role of paternal circadian rhythm for offspring health. Here, we disrupted circadian rhythm in male mice by night-restricted feeding and showed that paternal circadian disruption at conception is important for offspring feeding behavior, metabolic health, and oscillatory transcription. Mechanistically, our data suggest that the effect of paternal circadian disruption is not transferred to the offspring via the germ cells but initiated by corticosterone-based parental communication at conception and programmed during in utero development through a state of fetal growth restriction. These findings indicate paternal circadian health at conception as a newly identified determinant of offspring phenotypes.
Collapse
Affiliation(s)
- Maximilian Lassi
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| | - Archana Tomar
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| | - Gemma Comas-Armangué
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| | - Rebekka Vogtmann
- Department of Gynecology and Obstetrics-University Hospital Essen - Essen, Germany
| | - Dorieke J Dijkstra
- University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, Netherlands
| | - David Corujo
- Cancer and Leukemia Epigenetics and Biology Program, Josep Carreras Institute for Leukemia Research (IJC) Badalona, Spain
| | - Raffaele Gerlini
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
| | - Jonatan Darr
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| | - Fabienne Scheid
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| | - Jan Rozman
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50, Vestec, Czech Republic
| | - Antonio Aguilar-Pimentel
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
| | - Omry Koren
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel
| | - Marcus Buschbeck
- Cancer and Leukemia Epigenetics and Biology Program, Josep Carreras Institute for Leukemia Research (IJC) Badalona, Spain
- Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), 08916 Badalona, Spain
| | - Helmut Fuchs
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
| | - Susan Marschall
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
| | - Valerie Gailus-Durner
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
| | - Martin Hrabe de Angelis
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- German Center for Diabetes Research (DZD) Neuherberg, Germany
- German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany
- Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität München Freising, Germany
| | - Torsten Plösch
- University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, Netherlands
| | - Alexandra Gellhaus
- Department of Gynecology and Obstetrics-University Hospital Essen - Essen, Germany
| | - Raffaele Teperino
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany.
- German Center for Diabetes Research (DZD) Neuherberg, Germany
| |
Collapse
|
11
|
Liu W, Yuan D, Han M, Huang J, Xie Y. Development and validation of a sensitive LC-MS/MS method for simultaneous quantification of thirteen steroid hormones in human serum and its application to the study of type 2 diabetes mellitus. J Pharm Biomed Anal 2021; 199:114059. [PMID: 33848916 DOI: 10.1016/j.jpba.2021.114059] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Revised: 03/30/2021] [Accepted: 03/31/2021] [Indexed: 12/13/2022]
Abstract
Endogenous steroid hormones with similar structure, poor content and high efficacy are difficult and vital to be quantitatively detected. In this study, a validated method was established for the simultaneous quantification of thirteen steroids in human serum, and applied to the study of type 2 diabetes mellitus (T2DM). An ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry (UPLC-MS/MS) was developed for the simultaneous determination of thirteen steroid hormones in human serum, including androstenedione, corticosterone (B), cortisol (F), cortisone, 18-hydroxycortisol (18OHF), 11-deoxycorticosterone, 11-deoxycortisol, pregnenolone, progesterone, 17-hydroxyprogesterone, testosterone, androstanolone and estradiol. Under the optimum conditions, method was achieved with a BEH Shield RP18 column within 18 min. The lower limits of quantitation for steroids were 0.08-7.81 ng/mL. The intra- and inter-day precision for all the analytes were less than 15 %, and the accuracy ranged from -14.19 % to 12.89 % at three quality control levels. The proposed method, indicating high steady and sensitivity, was successfully applied to the quantification of thirteen steroids levels in serum from patients with T2DM and healthy individuals. The serum concentrations of 18OHF and F were significantly increased in the patients compared with the healthy individuals, while B was significantly decreased. The fold change was 1.98, 1.25 and 0.79 respectively. The ratio of 18OHF to B (18OHF/B) exhibited a 2.51-fold increase in T2DM patients and presented a more significant change. 18OHF/B was identified as a prospective serum marker, which deserves further attention.
Collapse
Affiliation(s)
- Wuwei Liu
- Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China
| | - Daoyi Yuan
- Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China
| | - Minlu Han
- Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China
| | - Jingwen Huang
- Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China
| | - Ying Xie
- Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
| |
Collapse
|
12
|
Olesti E, Boccard J, Visconti G, González-Ruiz V, Rudaz S. From a single steroid to the steroidome: Trends and analytical challenges. J Steroid Biochem Mol Biol 2021; 206:105797. [PMID: 33259940 DOI: 10.1016/j.jsbmb.2020.105797] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 11/02/2020] [Accepted: 11/24/2020] [Indexed: 12/23/2022]
Abstract
For several decades now, the analysis of steroids has been a key tool in the diagnosis and monitoring of numerous endocrine pathologies. Thus, the available methods used to analyze steroids in biological samples have dramatically evolved over time following the rapid pace of technology and scientific knowledge. This review aims to synthetize the advances in steroids' analysis, from classical approaches considering only a few steroids or a limited number of steroid ratios, up to the new steroid profiling strategies (steroidomics) monitoring large sets of steroids in biological matrices. In this context, the use of liquid chromatography coupled to mass spectrometry has emerged as the technique of choice for the simultaneous determination of a high number of steroids, including phase II metabolites, due to its sensitivity and robustness. However, the large dynamic range to be covered, the low natural abundance of some key steroids, the selectivity of the analytical methods, the extraction protocols, and the steroid ionization remain some of the current challenges in steroid analysis. This review provides an overview of the different analytical workflows available depending on the number of steroids under study. Special emphasis is given to sample treatment, acquisition strategy, data processing, steroid identification and quantification using LC-MS approaches. This work also outlines how the availability of steroid standards, the need for complementary analytical strategies and the improvement of calibration approaches are crucial for achieving complete steroidome quantification.
Collapse
Affiliation(s)
- Eulalia Olesti
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Julien Boccard
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Gioele Visconti
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Switzerland
| | - Víctor González-Ruiz
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Serge Rudaz
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Switzerland.
| |
Collapse
|